Univar Inc. announced today that its wholly-owned subsidiary, Univar USA Inc., has acquired all of the outstanding stock of Arrow Chemical, Inc., an importer and distributor of active pharmaceutical ingredients (API) and other specialty chemistries in the U.S. market.
Founded in 1982, Arrow Chemical sources a broad range of APIs, and nutritional and cosmetic ingredients from a broad network of suppliers in Asia, Western Europe, and the U.S. The company specializes in fine, niche chemistries, and works with customers and suppliers across the world in third-party manufacturing, custom chemical synthesis, finished dosage, and Abbreviated New Drug Application (ANDA) developments. Arrow Chemical is based in Greenwich, Conn., and services customers with truck, rail, and tanker deliveries through a nationwide third-party distribution network.
“We see strong growth opportunities for Univar in the pharmaceutical and nutraceutical market, and continue to focus our commercial capabilities for delivering a total solution set of products and services to customers,” said Univar President and Chief Executive Officer Erik Fyrwald. “Arrow Chemical has a strong base business with key pharmaceutical manufacturers and has built a solid global network of quality and reputable ingredient producers. This acquisition enhances the value we can deliver to our customers by expanding our existing offering with a complementary portfolio of APIs and other specialty ingredients essential to the formulation of generic and over-the-counter pharmaceuticals.”
“For more than 30 years, Arrow Chemical has been a business built around delivering outstanding service and value to our customers,” said Gary Trief, President, Arrow Chemical. “As we looked ahead to the future, we saw Univar as the ideal opportunity for providing the resources, talent, and unique global reach to expand and enhance what we can currently offer to our customers and suppliers. We look forward to leveraging the best of Arrow Chemical to help build a leadership role for Univar within the generic and OTC pharmaceutical ingredient market.”
Source: Univar
Neste Corporation’s Board of Directors has appointed Heikki Malinen, M.Sc. (Econ.), MBA (Harvard) as the President and CEO of Neste as of 2 November 2024, at the latest. Malinen joins Neste from Outokumpu Corporation where he has held the position of President and CEO since 2020.
Petrochemicals company Sasol has announced that CFO and executive director Hanré Rossouw will step down from his position, effective October 31. Sasol has started the process to appoint a successor. Rossouw will still oversee the publication of Sasol’s reports for the financial year ending June 30, to allow for a structured handover period.
Chemours announced its CFO Jonathan Lock has resigned from all positions within the company, according to an SEC 8-K filing on April 23. The resignation comes in the aftermath of the company announcing that Lock, former CEO Mark Newman, and principal accounting officer Camela Wisel, had been placed on administrative leave.
